Free Trial

Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics logo
$1.11 +0.03 (+2.78%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.10 -0.01 (-0.45%)
As of 05/22/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HOWL vs. PRME, INMB, TLSA, MOLN, ELDN, OGI, INBX, PRQR, HURA, and DMAC

Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

Werewolf Therapeutics vs.

Prime Medicine (NYSE:PRME) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.

Prime Medicine has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime MedicineN/A -107.87% -74.97%
Werewolf Therapeutics -578.80%-58.83%-38.45%

Werewolf Therapeutics received 5 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 70.00% of users gave Werewolf Therapeutics an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote.

CompanyUnderperformOutperform
Prime MedicineOutperform Votes
30
65.22%
Underperform Votes
16
34.78%
Werewolf TherapeuticsOutperform Votes
35
70.00%
Underperform Votes
15
30.00%

Prime Medicine currently has a consensus price target of $11.80, suggesting a potential upside of 859.35%. Werewolf Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 650.75%. Given Prime Medicine's higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.86
Werewolf Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Werewolf Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$3.85M41.99-$198.13M-$1.61-0.76
Werewolf Therapeutics$1.14M43.58-$37.37M-$1.67-0.66

Prime Medicine has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

In the previous week, Prime Medicine had 20 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 22 mentions for Prime Medicine and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.64 beat Prime Medicine's score of 0.02 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
0 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Werewolf Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 23.5% of Prime Medicine shares are held by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Prime Medicine beats Werewolf Therapeutics on 11 of the 19 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOWL vs. The Competition

MetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$49.81M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.739.0626.7119.71
Price / Sales43.58251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book0.366.456.774.50
Net Income-$37.37M$143.98M$3.23B$248.22M
7 Day PerformanceN/A0.38%0.48%-0.78%
1 Month Performance29.92%2.14%9.10%11.53%
1 Year Performance-78.49%-0.33%18.56%8.99%

Werewolf Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOWL
Werewolf Therapeutics
3.2641 of 5 stars
$1.11
+2.8%
$8.33
+650.8%
-77.3%$49.81M$1.14M-0.7340
PRME
Prime Medicine
3.6873 of 5 stars
$1.34
+3.1%
$13.14
+880.8%
-83.5%$175.76M$3.85M-0.65234Trending News
Analyst Forecast
Analyst Revision
INMB
INmune Bio
1.9258 of 5 stars
$7.64
+9.6%
$22.80
+198.4%
-29.9%$175.60M$14,000.00-3.5010Positive News
Gap Down
TLSA
Tiziana Life Sciences
0.93 of 5 stars
$1.50
-4.5%
N/A+69.1%$175.27MN/A0.008Gap Up
MOLN
Molecular Partners
1.9287 of 5 stars
$4.28
+4.4%
$12.00
+180.4%
+2.4%$172.81M$4.97M-1.99180Positive News
ELDN
Eledon Pharmaceuticals
2.1332 of 5 stars
$2.87
-0.7%
$12.50
+335.5%
+1.0%$171.86MN/A-1.4310News Coverage
Positive News
Analyst Upgrade
Analyst Revision
Gap Up
OGI
Organigram
0.4148 of 5 stars
$1.28
+8.5%
N/A-27.1%$171.31M$166.12M-3.37860High Trading Volume
INBX
Inhibrx
2.1855 of 5 stars
$11.71
+4.7%
N/A-63.6%$169.51M$200,000.000.00166
PRQR
ProQR Therapeutics
3.2189 of 5 stars
$1.59
-1.2%
$8.75
+450.3%
-12.9%$167.29M$18.91M-4.97180
HURA
TuHURA Biosciences
N/A$3.82
-4.3%
$12.67
+231.6%
N/A$166.86MN/A0.00N/AAnalyst Revision
DMAC
DiaMedica Therapeutics
1.4697 of 5 stars
$3.83
+4.6%
$8.00
+108.9%
+44.6%$164.14MN/A-6.8420Gap Up

Related Companies and Tools


This page (NASDAQ:HOWL) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners